Drug Trial Radar · NCT05248802
DLBS2411 Treatment For Functional Dyspepsia
Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Dec 9, 2022
Primary completion
Oct 1, 2025
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- Dexa Medica GroupIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients with functional dyspepsia (FD), and an additional 8 weeks after end of therapy (Week 12) for follow-up visit. The bioactive fraction of DLBS2411 has been proved at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its cytoprotective defense mechanism works through the promotion of cyclooxygenase-2 (COX-2) derived prostaglandin (PgE2) synthesis, thus promoting gastrointestinal submucosal blood-flow, stimulating secretion of gastric-epithelial mucous and bicarbonate; anti-oxidative activity; and endothelial-nitric oxide (NO) formation. The mechanism altogether demonstrated DLBS2411's protective capacity to the gastric and colon mucosa by promoting mucous synthesis and stimulating mucosal blood flow. Having such mechanisms of action, DLBS2411 is hypothesized to benefit subjects with gastric acid disorders such as in functional dyspepsia, gastro-intestinal reflux disease (GERD), peptic-ulcer, and irritable bowel syndrome (IBS).
Conditions
- Functional Dyspepsia
Interventions
Placebo caplet of DLBS2411Drug
1 caplet of placebo DLBS2411, twice daily
DLBS2411Drug
1 caplet of DLBS2411 250 mg, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Short-Form Nepean Dyspepsia Index (SF-NDI)Time frame: Week 4
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Department of Internal Medicine, Dr. Kariadi General Hospital
Semarang, Central Java, Indonesia
Department of Internal Medicine, Universitas Sebelas Maret (UNS) Hospital
Sukoharjo, Central Java, Indonesia
Department of Internal Medicine, Dr. Moewardi Hospital
Surakarta, Central Java, Indonesia
Department of Internal Medicine, Budhi Asih Hospital
Jakarta, DKI Jakarta, Indonesia
Department of Internal Medicine, Fatmawati General Hospital
Jakarta, DKI Jakarta, Indonesia
Department of Internal Medicine, Pasar Rebo Hospital
Jakarta, DKI Jakarta, Indonesia
Department of Internal Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Surabaya, East Java, Indonesia
Division of Gastroenterology Department of Internal Medicine Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo National General Hospital
Jakarta, Jakarta Special Capital Region, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.